Cargando…

Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy

There has been a resurgence of interest in aerosolization of antibiotics for treatment of patients with severe pneumonia caused by multidrug-resistant pathogens. A combination formulation of amikacin-fosfomycin is currently undergoing clinical testing although the exposure-response relationships of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sime, Fekade Bruck, Johnson, Adam, Whalley, Sarah, Santoyo-Castelazo, Anahi, Montgomery, A. Bruce, Walters, Kathie Ann, Lipman, Jeffrey, Hope, William W., Roberts, Jason A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2016
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192115/ https://www.ncbi.nlm.nih.gov/pubmed/27795380 http://dx.doi.org/10.1128/AAC.01763-16

Ejemplares similares

Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa
por: Heffernan, Aaron J., et al.
Publicado: (2021)

In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2017)

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model
por: Mohd Sazlly Lim, Sazlyna, et al.
Publicado: (2022)

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model
por: Avent, Minyon L., et al.
Publicado: (2022)

Deciphering pharmacokinetics and pharmacodynamics of fosfomycin
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2019)

How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?
por: Wong, Gloria, et al.
Publicado: (2014)

Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin–Resistant Enterococcus faecium in a Hollow Fiber Infection Model
por: Wang, Shuaishuai, et al.
Publicado: (2021)

Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing Klebsiella pneumoniae in an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Wang, Jin, et al.
Publicado: (2018)

Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review
por: Sime, Fekade Bruck, et al.
Publicado: (2012)

Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis
por: Heffernan, Aaron, et al.
Publicado: (2021)

Pharmacodynamics of Ceftriaxone, Ertapenem, Fosfomycin and Gentamicin in Neisseria gonorrhoeae
por: Gubenšek, Urša, et al.
Publicado: (2022)

Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant Klebsiella Pneumoniae: Exploring A Colistin Sparing Protocol
por: AL-Quraini, Manawr, et al.
Publicado: (2022)

Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort
por: Turner, Richard Myles, et al.
Publicado: (2018)

Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen
por: Kato, Hideo, et al.
Publicado: (2017)

Amikacin-loaded niosome nanoparticles improve amikacin activity against antibiotic-resistant Klebsiella pneumoniae strains
por: Rahmati, Mohamad, et al.
Publicado: (2022)

Heteroresistance to Amikacin in Carbapenem-Resistant Klebsiella pneumoniae Strains
por: Zhang, Feiyang, et al.
Publicado: (2021)

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
por: Logre, Elsa, et al.
Publicado: (2020)

Synergistic activity of fosfomycin–meropenem and fosfomycin–colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2020)

Comparison of amikacin with fosfomycin as an add-on to ciprofloxacin for antibiotic prophylaxis in transrectal prostate biopsy: A single-center retrospective study
por: Yu, Seong Hyeon, et al.
Publicado: (2022)

Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model
por: Islam, Kamrul, et al.
Publicado: (2022)

Challenges in Antifungal Therapy in Diabetes Mellitus
por: Mohd Sazlly Lim, Sazlyna, et al.
Publicado: (2020)

Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series
por: Davis, Kala K, et al.
Publicado: (2007)

Evaluation of the combination treatments with intravenous fosfomycin for carbapenem-resistant Klebsiella pneumoniae
por: Önal, Uğur, et al.
Publicado: (2023)

In Vitro Antibacterial Interaction of Doripenem and Amikacin against Multidrug-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates
por: Loho, Tonny, et al.
Publicado: (2018)

Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model
por: Zuluaga, Andres F., et al.
Publicado: (2015)

Coexistence of Fosfomycin and Colistin Resistance in Klebsiella pneumoniae: Whole-Genome Shotgun Sequencing
por: Veeraraghavan, Balaji, et al.
Publicado: (2016)

In Vitro Activity of Carbapenems Alone and in Combination With Amikacin Against KPC-Producing Klebsiella Pneumoniae
por: Le, Jennifer, et al.
Publicado: (2011)

Effect of Gold Nanostars Plus Amikacin against Carbapenem-Resistant Klebsiella pneumoniae Biofilms
por: Aguilera-Correa, John Jairo, et al.
Publicado: (2022)

Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings
por: Darlow, Christopher A, et al.
Publicado: (2022)

Dose Optimization of Combined Linezolid and Fosfomycin against Enterococcus by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Mao, Jun, et al.
Publicado: (2021)

Nitrofurantoin and Fosfomycin for Extended Spectrum Beta-lactamases Producing Escherichia coli and Klebsiella pneumoniae
por: Tulara, Neeraj Kumar
Publicado: (2018)

In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2018)

Transporter Genes and fosA Associated With Fosfomycin Resistance in Carbapenem-Resistant Klebsiella pneumoniae
por: Wang, Yu-Ping, et al.
Publicado: (2022)

Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant Klebsiella pneumoniae in vitro
por: Yu, Lan, et al.
Publicado: (2019)

Fosfomycin (FOS) Plus Meropenem (MER) Suppresses Resistance Emergence Against P. aeruginosa (PA) PAO1 in the Hollow Fiber Infection Model (HFIM)
por: Louie, Arnold, et al.
Publicado: (2017)

Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model
por: Abbott, Iain J., et al.
Publicado: (2022)

Tigecycline-Amikacin Combination Effectively Suppresses the Selection of Resistance in Clinical Isolates of KPC-Producing Klebsiella pneumoniae
por: Ni, Wentao, et al.
Publicado: (2016)

234. Reversal of Carbapenem and Amikacin Susceptibilities in Isogenic Klebsiella pneumoniae From a Patient with Persistent Bacteriuria
por: Rojas, Laura J, et al.
Publicado: (2019)

Comparative Proteomics Demonstrates Altered Metabolism Pathways in Cotrimoxazole- Resistant and Amikacin-Resistant Klebsiella pneumoniae Isolates
por: Shen, Chunmei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vr147h5c3koigvbrtmqcvncka9